Reimbursement Expansion To Fuel China Pharma Growth In 2011 (Part 1 of 2)

HONG KONG - China's pharmaceutical market is expected to grow around 26% in the coming year with much of the growth fueled by continued implementation of the government's Essential Drug List (EDL) and reimbursement expansion via government insurance plans, said Katherine Lu, senior analyst for China healthcare at Oppenheimer & Co